{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:28:39Z","timestamp":1793312919941,"version":"4.5.0"},"reference-count":209,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"TrevisoAIL"},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02455-y","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:43:05Z","timestamp":1761122585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"24","author":[{"given":"F.","family":"Lo Schiavo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Salvesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jandoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pirini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Garbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"11","key":"2455_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112991","volume":"15","author":"TR Haage","year":"2023","unstructured":"Haage TR, Schraven B, Mougiakakos D, Fischer T. How ITD insertion sites orchestrate the biology and disease of FLT3-ITD-mutated acute myeloid leukemia. Cancers (Basel). 2023;15(11):2991.","journal-title":"Cancers (Basel)"},{"key":"2455_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00161-7","volume":"9","author":"J Yu","year":"2020","unstructured":"Yu J, Li Y, Zhang D, Wan D, Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020;9:4.","journal-title":"Exp Hematol Oncol"},{"issue":"2","key":"2455_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"23","key":"2455_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"7","key":"2455_CR5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","volume":"20","author":"J Cloos","year":"2006","unstructured":"Cloos J, Goemans BF, Hess CJ, et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia. 2006;20(7):1217\u201320.","journal-title":"Leukemia"},{"issue":"8","key":"2455_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.5858\/2009-0292-OA.1","volume":"134","author":"SR McCormick","year":"2010","unstructured":"McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med. 2010;134(8):1143\u201351.","journal-title":"Arch Pathol Lab Med"},{"issue":"19","key":"2455_CR7","doi-asserted-by":"publisher","first-page":"4945","DOI":"10.1182\/bloodadvances.2020002904","volume":"4","author":"MT Voso","year":"2020","unstructured":"Voso MT, Larson RA, Jones D, et al. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Adv. 2020;4(19):4945\u201354.","journal-title":"Blood Adv"},{"issue":"2","key":"2455_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/OP.22.00342","volume":"19","author":"JH Cooperrider","year":"2023","unstructured":"Cooperrider JH, Shukla N, Nawas MT, Patel AA. The cup runneth over: treatment strategies for newly diagnosed acute myeloid leukemia. JCO Oncol Pract. 2023;19(2):74\u201385.","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"2455_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000606","volume":"4","author":"K Tzogani","year":"2019","unstructured":"Tzogani K, Yu Y, Meulendijks D, et al. European medicines agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis. ESMO Open. 2019;4(6):e000606.","journal-title":"ESMO Open"},{"issue":"1\u20132","key":"2455_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41417-019-0120-z","volume":"27","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Y, Wang F, et al. The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia. Cancer Gene Ther. 2020;27(1\u20132):81\u20138.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"2455_CR11","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","volume":"103","author":"SA Armstrong","year":"2004","unstructured":"Armstrong SA, Mabon ME, Silverman LB, et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004;103(9):3544\u20136.","journal-title":"Blood"},{"issue":"11","key":"2455_CR12","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.3324\/haematol.2017.169870","volume":"102","author":"H Fedders","year":"2017","unstructured":"Fedders H, Alsadeq A, Schm\u00e4h J, et al. The role of constitutive activation of FMS-related tyrosine kinase-3 and nras\/kras mutational status in infants with KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2017;102(11):e438\u201342.","journal-title":"Haematologica"},{"issue":"2","key":"2455_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-023-02511-8","volume":"130","author":"A Gutierrez-Camino","year":"2024","unstructured":"Gutierrez-Camino A, Richer C, Ouimet M, et al. Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia. Br J Cancer. 2024;130(2):317\u201326.","journal-title":"Br J Cancer"},{"key":"2455_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040723","author":"H Hayashi","year":"2024","unstructured":"Hayashi H, Makimoto A, Yuza Y. Treatment of pediatric acute lymphoblastic leukemia: a historical perspective. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16040723.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2455_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12098-023-04635-4","volume":"91","author":"J Sidhu","year":"2024","unstructured":"Sidhu J, Gogoi MP, Krishnan S, Saha V. Relapsed acute lymphoblastic leukemia. Indian J Pediatr. 2024;91(2):158\u201367.","journal-title":"Indian J Pediatr"},{"key":"2455_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114338","volume":"212","author":"DT Kristensen","year":"2024","unstructured":"Kristensen DT, J\u00e5tun TL, Simonsen MR, et al. Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998\u20132020 \u2013 a Danish nationwide population-based cohort study. Eur J Cancer. 2024;212:114338.","journal-title":"Eur J Cancer"},{"issue":"3","key":"2455_CR17","first-page":"166","volume":"17","author":"S Paul","year":"2019","unstructured":"Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ. Treatment of relapsed\/refractory acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2019;17(3):166\u201375.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"3","key":"2455_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/bjh.18877","volume":"202","author":"SS Ge","year":"2023","unstructured":"Ge SS, Qiu QC, Dai HP, et al. Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. Br J Haematol. 2023;202(3):539\u201349.","journal-title":"Br J Haematol"},{"issue":"1","key":"2455_CR19","first-page":"1","volume":"13","author":"X Zhao","year":"2022","unstructured":"Zhao X, Wang P, Diedrich JD, et al. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nat Commun. 2022;13(1):1\u201311.","journal-title":"Nat Commun"},{"issue":"11","key":"2455_CR20","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/2159-8290.CD-21-0145","volume":"11","author":"LE Montefiori","year":"2021","unstructured":"Montefiori LE, Bendig S, Gu Z, et al. Enhancer hijacking drives oncogenic BCL11B expression in lineage-ambiguous stem cell leukemia. Cancer Discov. 2021;11(11):2846\u201367.","journal-title":"Cancer Discov"},{"issue":"8","key":"2455_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1182\/blood.2019004684","volume":"136","author":"M Yang","year":"2020","unstructured":"Yang M, Safavi S, Woodward EL, et al. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood. 2020;136(8):946\u201356.","journal-title":"Blood"},{"issue":"24","key":"2455_CR22","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1182\/blood.2021014723","volume":"139","author":"M Passet","year":"2022","unstructured":"Passet M, Kim R, Gachet S, et al. Concurrent CDX2 cis -deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL. Blood. 2022;139(24):3505\u201318.","journal-title":"Blood"},{"issue":"24","key":"2455_CR23","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood.2022015444","volume":"139","author":"S Kimura","year":"2022","unstructured":"Kimura S, Montefiori L, Iacobucci I, et al. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022;139(24):3519\u201331.","journal-title":"Blood"},{"key":"2455_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106198","volume":"85","author":"J Shang","year":"2019","unstructured":"Shang J, Chen WM, Liu S, et al. Circpan3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy. Leuk Res. 2019;85:106198.","journal-title":"Leuk Res"},{"issue":"July 2020","key":"2455_CR25","doi-asserted-by":"publisher","first-page":"114348","DOI":"10.1016\/j.bcp.2020.114348","volume":"183","author":"V Marensi","year":"2021","unstructured":"Marensi V, Keeshan KR, MacEwan DJ. Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors. Biochem Pharmacol. 2021;183(July 2020):114348.","journal-title":"Biochem Pharmacol"},{"issue":"Suppl 3","key":"2455_CR26","first-page":"1","volume":"10","author":"R Berenstein","year":"2015","unstructured":"Berenstein R, Class III. Receptor tyrosine kinases in acute leukemia \u2013 biological functions and modern laboratory analysis. Biomark Insights. 2015;10(Suppl 3):1\u201314.","journal-title":"Biomark Insights"},{"issue":"1","key":"2455_CR27","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","volume":"6","author":"T Grafone","year":"2012","unstructured":"Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6(1):e8.","journal-title":"Oncol Rev"},{"issue":"4","key":"2455_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202200680","volume":"24","author":"F Yang","year":"2023","unstructured":"Yang F, Tan Y, Wu C, et al. dSTORM-based single-cell protein quantitative analysis can effectively evaluate the degradation ability of protacs. Chembiochem. 2023;24(4):e202200680.","journal-title":"Chembiochem"},{"issue":"9","key":"2455_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138257","volume":"10","author":"G Volpe","year":"2015","unstructured":"Volpe G, Clarke M, Garc\u00eca P, et al. Regulation of the Flt3 gene in haematopoietic stem and early progenitor cells. PLoS ONE. 2015;10(9):e0138257.","journal-title":"PLoS ONE"},{"issue":"3","key":"2455_CR30","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","volume":"99","author":"JU Kazi","year":"2019","unstructured":"Kazi JU, R\u00f6nnstrand L. FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications. Physiol Rev. 2019;99(3):1433\u201366.","journal-title":"Physiol Rev"},{"key":"2455_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00228","author":"EV Rothenberg","year":"2019","unstructured":"Rothenberg EV, Hosokawa H, Ungerb\u00e4ck J. Mechanisms of action of hematopoietic transcription factor PU.1 in initiation of T-cell development. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.00228.","journal-title":"Front Immunol"},{"issue":"1","key":"2455_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","volume":"8","author":"A Zhao","year":"2023","unstructured":"Zhao A, Zhou H, Yang J, Li M, Niu T. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct Target Ther. 2023;8(1):1\u201340.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2455_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061115","volume":"18","author":"P Tsapogas","year":"2017","unstructured":"Tsapogas P, Mooney CJ, Brown G, Rolink A. The cytokine Flt3-ligand in normal and malignant hematopoiesis. Int J Mol Sci. 2017;18(6):1115.","journal-title":"Int J Mol Sci"},{"key":"2455_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13:155.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2455_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00687-5","volume":"12","author":"SP Desikan","year":"2022","unstructured":"Desikan SP, Daver N, DiNardo C, Kadia T, Konopleva M, Ravandi F. Resistance to targeted therapies: delving into FLT3 and IDH. Blood Cancer J. 2022;12(6):1\u20138.","journal-title":"Blood Cancer J"},{"issue":"8","key":"2455_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9081051","volume":"9","author":"B Moser","year":"2021","unstructured":"Moser B, Edtmayer S, Witalisz-Siepracka A, Stoiber D. The ups and downs of STAT inhibition in acute myeloid leukemia. Biomedicines. 2021;9(8):1051.","journal-title":"Biomedicines"},{"issue":"9","key":"2455_CR37","first-page":"e45765","volume":"15","author":"M Jalte","year":"2023","unstructured":"Jalte M, Abbassi M, Mouhi H, El, Belghiti HD, Ahakoud M, Bekkari H. FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies. Cureus. 2023;15(9):e45765.","journal-title":"Cureus"},{"key":"2455_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117788","volume":"182","author":"J Rataj","year":"2025","unstructured":"Rataj J, Gorecki L, Muthna D, et al. Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges. Biomed Pharmacother. 2025;182:117788.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2455_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41375-021-01462-4","volume":"36","author":"A Charlet","year":"2022","unstructured":"Charlet A, Kappenstein M, Keye P, et al. The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML. Leukemia. 2022;36(3):701\u201311.","journal-title":"Leukemia"},{"key":"2455_CR40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024018","author":"C Choudhary","year":"2007","unstructured":"Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007. https:\/\/doi.org\/10.1182\/blood-2006-05-024018.","journal-title":"Blood"},{"key":"2455_CR41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2942","author":"C Choudhary","year":"2005","unstructured":"Choudhary C, Schw\u00e4ble J, Brandts C, et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood. 2005. https:\/\/doi.org\/10.1182\/blood-2004-07-2942.","journal-title":"Blood"},{"issue":"2","key":"2455_CR42","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-022-01785-w","volume":"37","author":"G Massacci","year":"2023","unstructured":"Massacci G, Venafra V, Latini S, et al. A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients. Leukemia. 2023;37(2):288\u201397.","journal-title":"Leukemia"},{"issue":"12","key":"2455_CR43","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377.","journal-title":"Blood"},{"issue":"5","key":"2455_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/17474086.2023.2202849","volume":"16","author":"H Reikvam","year":"2023","unstructured":"Reikvam H. Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia. Expert Rev Hematol. 2023;16(5):317\u201323.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2455_CR45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312\u201322.","journal-title":"Cancer Sci"},{"key":"2455_CR46","unstructured":"Okabe A, Guirales F, Zhao D, Tirado CA. FLT3 gene involvement in B-cell acute lymphoblastic leukemia (B-ALL). J Assoc Genet Technol. 2021;47:7\u201315."},{"issue":"February","key":"2455_CR47","doi-asserted-by":"publisher","first-page":"104725","DOI":"10.1016\/j.phrs.2020.104725","volume":"155","author":"R Roskoski","year":"2020","unstructured":"Roskoski R. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. Pharmacol Res. 2020;155(February):104725.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2455_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02587-3","volume":"15","author":"IF Alarbeed","year":"2021","unstructured":"Alarbeed IF, Wafa A, Moassass F, et al. De novo adult acute myeloid leukemia with two new mutations in juxtatransmembrane domain of the FLT3 gene: a case report. J Med Case Rep. 2021;15(1):22.","journal-title":"J Med Case Rep"},{"issue":"7","key":"2455_CR49","doi-asserted-by":"publisher","first-page":"10931","DOI":"10.18632\/oncotarget.14539","volume":"8","author":"B Nguyen","year":"2017","unstructured":"Nguyen B, Williams AB, Young DJ, et al. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Oncotarget. 2017;8(7):10931\u201344.","journal-title":"Oncotarget"},{"issue":"4","key":"2455_CR50","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"6","key":"2455_CR51","first-page":"6766","volume":"18","author":"S Tao","year":"2019","unstructured":"Tao S, Wang C, Chen Y, et al. Prognosis and outcome of patients with acute myeloid leukemia based on FLT3\u2013ITD mutation with or without additional abnormal cytogenetics. Oncol Lett. 2019;18(6):6766\u201374.","journal-title":"Oncol Lett"},{"key":"2455_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.144195","volume":"726","author":"M Lyu","year":"2020","unstructured":"Lyu M, Liao H, Shuai X, Jin Y, Su J, Zheng Q. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan. Gene. 2020;726:144195.","journal-title":"Gene"},{"issue":"3","key":"2455_CR53","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41375-024-02498-y","volume":"39","author":"N Anabtawi","year":"2025","unstructured":"Anabtawi N, Nicolet D, Alotaibi N, et al. Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of alliance studies. Leukemia. 2025;39(3):623\u201331.","journal-title":"Leukemia"},{"issue":"21","key":"2455_CR54","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and Azacitidine. Blood. 2024;144(21):2211\u201322.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2455_CR55","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1182\/blood-2024-207703","volume":"144","author":"P Olson","year":"2024","unstructured":"Olson P, Gabdoulline R, Shahswar R, et al. Prognostic impact of subclinical FLT3-ITD microclones in patients with acute myeloid leukemia. Blood. 2024;144(Supplement 1):847\u2013847.","journal-title":"Blood"},{"issue":"2","key":"2455_CR56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/bloodadvances.2024014672","volume":"9","author":"R Joudinaud","year":"2025","unstructured":"Joudinaud R, Boudry A, Fenwarth L, et al. Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia. Blood Adv. 2025;9(2):365\u201374.","journal-title":"Blood Adv"},{"issue":"17","key":"2455_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179581","volume":"25","author":"L Zhao","year":"2024","unstructured":"Zhao L, Chen H, Lan F, et al. Distinct FLT3 pathways gene expression profiles in pediatric de novo acute lymphoblastic and myeloid leukemia with FLT3 mutations: implications for targeted therapy. Int J Mol Sci. 2024;25(17):9581.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2455_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.arcmed.2020.10.013","volume":"52","author":"J Vela-Ojeda","year":"2021","unstructured":"Vela-Ojeda J, Cardenas PV, Garcia-Ruiz Esparza MA, et al. FLT3-ITD and CD135 over-expression are frequent findings of poor survival in adult patients with acute leukemias. Arch Med Res. 2021;52(2):217\u201323.","journal-title":"Arch Med Res"},{"issue":"9","key":"2455_CR59","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022;54(9):1376\u201389.","journal-title":"Nat Genet"},{"key":"2455_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102475","author":"L Lo Nigro","year":"2022","unstructured":"Lo Nigro L, Andriano N, Buldini B, et al. FLT3-ITD in children with early T\u2010cell precursor (ETP) acute lymphoblastic leukemia: incidence and potential target for monitoring minimal residual disease (MRD). Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14102475.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2455_CR61","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/jha2.862","volume":"5","author":"H Wang","year":"2024","unstructured":"Wang H, Ni R, Wang A, Liu B. CD117 expression predicted FLT3 mutation in T-cell acute lymphoblastic leukemia. EJHaem. 2024;5(1):294\u20135.","journal-title":"EJHaem"},{"issue":"12","key":"2455_CR62","doi-asserted-by":"publisher","first-page":"13886","DOI":"10.18632\/oncotarget.7356","volume":"7","author":"M Messina","year":"2016","unstructured":"Messina M, Chiaretti S, Wang J, et al. Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget. 2016;7(12):13886\u2013901.","journal-title":"Oncotarget"},{"issue":"2","key":"2455_CR63","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296\u2013307.","journal-title":"Nat Genet"},{"issue":"1","key":"2455_CR64","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1007\/s12032-013-0462-6","volume":"30","author":"NN Kabir","year":"2013","unstructured":"Kabir NN, R\u00f6nnstrand L, Kazi JU. FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL). Med Oncol. 2013;30(1):0\u20136.","journal-title":"Med Oncol"},{"key":"2455_CR65","unstructured":"Ding Y, Zhou Y, Yuan J, Khanna A, Zhang L. FLT3-ITD in Acute Leukemia of Ambiguous Lineage Case Study Acute Leukemias of Ambiguous Lineage with FLT3-ITD, Report of 4 Cases. 2022;2:1\u201310."},{"issue":"10","key":"2455_CR66","first-page":"2011","volume":"62","author":"A Azari-Yam","year":"2016","unstructured":"Azari-Yam A, Tavakkoly-Bazzaz J, Semnani Y, et al. FLT3 gene mutation profile and prognosis in adult acute myeloid leukemia. Clin Lab. 2016;62(10):2011\u20137.","journal-title":"Clin Lab"},{"issue":"10","key":"2455_CR67","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/gcc.22765","volume":"58","author":"AJ de Smith","year":"2019","unstructured":"de Smith AJ, Lavoie G, Walsh KM, et al. Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. Genes Chromosomes Cancer. 2019;58(10):723\u201330.","journal-title":"Genes Chromosomes Cancer"},{"issue":"76","key":"2455_CR68","doi-asserted-by":"publisher","first-page":"34240","DOI":"10.18632\/oncotarget.26045","volume":"9","author":"K Katayama","year":"2018","unstructured":"Katayama K, Noguchi K, Sugimoto Y. Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia. Oncotarget. 2018;9(76):34240\u201358.","journal-title":"Oncotarget"},{"issue":"2","key":"2455_CR69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/bjh.18991","volume":"203","author":"S Travaglini","year":"2023","unstructured":"Travaglini S, Gurnari C, Antonelli S, et al. Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: a proof of concept. Br J Haematol. 2023;203(2):327\u201330.","journal-title":"Br J Haematol"},{"issue":"7","key":"2455_CR70","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/bloodadvances.2020003699","volume":"5","author":"B Spitzer","year":"2021","unstructured":"Spitzer B, Dela Cruz FS, Ibanez Sanchez GD, et al. ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia presenting in an infant: an entity distinct from JMML. Blood Adv. 2021;5(7):1899\u2013902.","journal-title":"Blood Adv"},{"issue":"9","key":"2455_CR71","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","volume":"34","author":"G Tang","year":"2021","unstructured":"Tang G, Tam W, Short NJ, et al. Myeloid\/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021;34(9):1673\u201385.","journal-title":"Mod Pathol"},{"issue":"8","key":"2455_CR72","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","volume":"118","author":"C Walz","year":"2011","unstructured":"Walz C, Erben P, Ritter M, et al. Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood. 2011;118(8):2239\u201342.","journal-title":"Blood"},{"issue":"10","key":"2455_CR73","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/leu.2014.168","volume":"28","author":"L Falchi","year":"2014","unstructured":"Falchi L, Mehrotra M, Newberry KJ, et al. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with Sorafenib and allogeneic stem cell transplant. Leukemia. 2014;28(10):2090\u20132.","journal-title":"Leukemia"},{"issue":"10","key":"2455_CR74","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/leu.2017.240","volume":"31","author":"M Jawhar","year":"2017","unstructured":"Jawhar M, Naumann N, Knut M, et al. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia. 2017;31(10):2271\u20133.","journal-title":"Leukemia"},{"issue":"2","key":"2455_CR75","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41375-019-0549-y","volume":"34","author":"AK Chao","year":"2020","unstructured":"Chao AK, Meyer JA, Lee AG, et al. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to Sorafenib identified by RNA sequencing. Leukemia. 2020;34(2):662\u20136.","journal-title":"Leukemia"},{"key":"2455_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106460","volume":"99","author":"H Shao","year":"2020","unstructured":"Shao H, Wang W, Song J, et al. Myeloid\/lymphoid neoplasms with eosinophilia and FLT3 rearrangement. Leuk Res. 2020;99:106460.","journal-title":"Leuk Res"},{"issue":"4","key":"2455_CR77","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1097\/MPH.0000000000001890","volume":"43","author":"MC Munthe-Kaas","year":"2021","unstructured":"Munthe-Kaas MC, Forthun RB, Brendehaug A, et al. Partial response to Sorafenib in a child with a myeloid\/lymphoid neoplasm, eosinophilia, and a ZMYM2-FLT3 fusion. J Pediatr Hematol Oncol. 2021;43(4):e508\u201311.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9","key":"2455_CR78","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/imcb.12484","volume":"99","author":"KR Wilson","year":"2021","unstructured":"Wilson KR, Villadangos JA, Mintern JD. Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy. Immunol Cell Biol. 2021;99(9):962\u201371.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"2455_CR79","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3324\/haematol.2015.124032","volume":"100","author":"MP Garcia-Cuellar","year":"2015","unstructured":"Garcia-Cuellar MP, Steger J, Fuller E, Hetzner K, Slany RK. Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica. 2015;100(7):905\u201313.","journal-title":"Haematologica"},{"issue":"7","key":"2455_CR80","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/leu.2013.23","volume":"27","author":"G Volpe","year":"2013","unstructured":"Volpe G, Walton DS, Del Pozzo W, et al. C\/EBP\u03b1 and MYB regulate FLT3 expression in AML. Leukemia. 2013;27(7):1487\u201396.","journal-title":"Leukemia"},{"issue":"11","key":"2455_CR81","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/onc.2016.318","volume":"36","author":"A Staffas","year":"2017","unstructured":"Staffas A, Arabanian LS, Wei SY, et al. Upregulation of Flt3 is a passive event in Hoxa9\/Meis1-induced acute myeloid leukemia in mice. Oncogene. 2017;36(11):1516\u201324.","journal-title":"Oncogene"},{"issue":"3","key":"2455_CR82","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/leu.2014.231","volume":"29","author":"D Gerloff","year":"2015","unstructured":"Gerloff D, Grundler R, Wurm AA, et al. NF-\u03baB\/STAT5\/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid. leukemia. Leukemia. 2015;29(3):535\u201347.","journal-title":"Leukemia"},{"issue":"5","key":"2455_CR83","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.exphem.2014.01.001","volume":"42","author":"JJ Dolence","year":"2014","unstructured":"Dolence JJ, Gwin KA, Shapiro MB, Medina KL. Flt3 signaling regulates the proliferation, survival, and maintenance of multipotent hematopoietic progenitors that generate {B} cell precursors. Exp Hematol. 2014;42(5):380\u2013e3933.","journal-title":"Exp Hematol"},{"issue":"2","key":"2455_CR84","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/ard-2022-222708","volume":"82","author":"J Tu","year":"2023","unstructured":"Tu J, Chen W, Fang Y, et al. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes. Ann Rheum Dis. 2023;82(2):198\u2013211.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2455_CR85","doi-asserted-by":"publisher","first-page":"e64800","DOI":"10.1371\/journal.pone.0064800","volume":"8","author":"X Wu","year":"2013","unstructured":"Wu X, Satpathy AT, Kc W, Liu P, Murphy TL, Murphy KM. Bcl11a Controls Flt3 Expression in Early Hematopoietic Progenitors and Is Required for pDC Development In Vivo. PLoS One. 2013;8(5):e64800 Kovats S ed.","journal-title":"PLoS One."},{"issue":"11","key":"2455_CR86","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.4049\/jimmunol.0904203","volume":"185","author":"K Gwin","year":"2010","unstructured":"Gwin K, Frank E, Bossou A, Medina KL. Hoxa9 regulates Flt3 in lymphohematopoietic progenitors. J Immunol. 2010;185(11):6572\u201383.","journal-title":"J Immunol"},{"issue":"1","key":"2455_CR87","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2004-12-4664","volume":"106","author":"GG Wang","year":"2005","unstructured":"Wang GG, Pasillas MP, Kamps MP. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus. Blood. 2005;106(1):254\u201364.","journal-title":"Blood"},{"key":"2455_CR88","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/978-3-031-62731-6_18","volume":"1459","author":"S Aryal","year":"2024","unstructured":"Aryal S, Lu R. HOXA9 regulome and Pharmacological interventions in leukemia. Adv Exp Med Biol. 2024;1459:405\u201330.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"2455_CR89","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.3324\/haematol.2022.281151","volume":"108","author":"BK Sahoo","year":"2023","unstructured":"Sahoo BK, Lin YC, Tu CF, et al. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia. Haematologica. 2023;108(5):1284\u201399.","journal-title":"Haematologica"},{"issue":"6","key":"2455_CR90","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.4049\/jimmunol.1800244","volume":"201","author":"H Guo","year":"2018","unstructured":"Guo H, Barberi T, Suresh R, Friedman AD. Progression from the common lymphoid progenitor to b\/myeloid preprob and prob precursors during B lymphopoiesis requires C\/EBP\u03b1. J Immunol. 2018;201(6):1692\u2013704.","journal-title":"J Immunol"},{"issue":"9","key":"2455_CR91","first-page":"1","volume":"2019","author":"A Khalid","year":"2019","unstructured":"Khalid A, Aslam S, Ahmed M, Hasnain S, Aslam A. Risk assessment of FLT3 and PAX5 variants in B-acute lymphoblastic leukemia: a case-control study in a Pakistani cohort. PeerJ. 2019;2019(9):1\u201315.","journal-title":"PeerJ"},{"key":"2455_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1023606","volume":"12","author":"Z Jia","year":"2022","unstructured":"Jia Z, Gu Z. PAX5 alterations in B-cell acute lymphoblastic leukemia. Front Oncol. 2022;12:1023606.","journal-title":"Front Oncol"},{"issue":"8","key":"2455_CR93","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/bloodadvances.2020003643","volume":"5","author":"CP Poubel","year":"2021","unstructured":"Poubel CP, Boroni M, Emerenciano M. 13q12.2 deletions and FLT3 overexpression in acute leukemias. Blood Adv. 2021;5(8):2075\u20138.","journal-title":"Blood Adv"},{"issue":"7","key":"2455_CR94","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.exphem.2016.04.011","volume":"44","author":"M Griffith","year":"2016","unstructured":"Griffith M, Griffith OL, Krysiak K, et al. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol. 2016;44(7):603\u201313.","journal-title":"Exp Hematol"},{"issue":"3","key":"2455_CR95","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/leu.2014.281","volume":"29","author":"T Kato","year":"2015","unstructured":"Kato T, Sakata-Yanagimoto M, Nishikii H, et al. Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia. 2015;29(3):576\u201385.","journal-title":"Leukemia"},{"issue":"23","key":"2455_CR96","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1182\/blood.V126.23.3784.3784","volume":"126","author":"X Jiang","year":"2015","unstructured":"Jiang X, Bugno J, Hu C, et al. Targeted treatment of FLT3 -overexpressing acute myeloid leukemia with MiR-150 nanoparticles guided by conjugated FLT3 ligand peptides. Blood. 2015;126(23):3784.","journal-title":"Blood"},{"issue":"2","key":"2455_CR97","first-page":"2885","volume":"17","author":"J Cheng","year":"2018","unstructured":"Cheng J, Qu L, Wang J, Cheng L, Wang Y. High expression of FLT3 is a risk factor in leukemia. Mol Med Rep. 2018;17(2):2885\u201392.","journal-title":"Mol Med Rep"},{"key":"2455_CR98","volume":"23","author":"D Kim","year":"2025","unstructured":"Kim D, Sutamtewagul G, Yu Y. FLT3 and NPM1 mRNA expression-based risk stratification of de novo acute myeloid leukemia. Leuk Res Rep. 2025;23:100494.","journal-title":"Leuk Res Rep"},{"key":"2455_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70069","author":"FM Hormann","year":"2025","unstructured":"Hormann FM, \u00d8stergaard A, van den Broek S, et al. Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia. HemaSphere. 2025. https:\/\/doi.org\/10.1002\/hem3.70069.","journal-title":"HemaSphere"},{"issue":"2","key":"2455_CR100","first-page":"172","volume":"142","author":"Z Li","year":"2023","unstructured":"Li Z, Chang TC, Junco JJ, et al. Genomic landscape of down syndrome-associated acute lymphoblastic leukemia. Blood. 2023;142(2):172\u201384.","journal-title":"Blood"},{"key":"2455_CR101","doi-asserted-by":"crossref","unstructured":"Tremblay CS, Saw J, Yan F et al. Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia. Leukemia January 23, 2025;39:577\u201389.","DOI":"10.1038\/s41375-024-02491-5"},{"key":"2455_CR102","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/S2152-2650(23)00967-9","volume":"23","author":"L Montefiori","year":"2023","unstructured":"Montefiori L, Iacobucci I, Budhraja A, et al. ALL-594 preclinical assessment of dual FLT3 and BCL-2 Inhibition in lineage ambiguous leukemia. Clin Lymphoma Myeloma Leuk. 2023;23:S255\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2455_CR103","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/ng.3535","volume":"48","author":"T Yasuda","year":"2016","unstructured":"Yasuda T, Tsuzuki S, Kawazu M, et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016;48(5):569\u201374.","journal-title":"Nat Genet"},{"issue":"1","key":"2455_CR104","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3324\/haematol.2016.151035","volume":"102","author":"S Hirabayashi","year":"2017","unstructured":"Hirabayashi S, Ohki K, Nakabayashi K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102(1):118\u201329.","journal-title":"Haematologica"},{"issue":"45","key":"2455_CR105","doi-asserted-by":"publisher","first-page":"31053","DOI":"10.1074\/jbc.M114.568287","volume":"289","author":"C Onish","year":"2014","unstructured":"Onish C, Mori-Kimachi S, Hirade T, et al. Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12\/Cxcr4 signaling axis. J Biol Chem. 2014;289(45):31053\u201365.","journal-title":"J Biol Chem"},{"issue":"Supplement1","key":"2455_CR106","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2019-126433","volume":"134","author":"T Kupsa","year":"2019","unstructured":"Kupsa T, Horacek JM, Jebavy L, Zak P. The influence of FLT3-ITD mutation on baseline levels of selected cytokines and soluble adhesion molecules in acute myeloid leukemia with mutated NPM-1. Blood. 2019;134(Supplement1):5111\u20135111.","journal-title":"Blood"},{"issue":"1","key":"2455_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48687-z","volume":"9","author":"T Cao","year":"2019","unstructured":"Cao T, Jiang N, Liao H, Shuai X, Su J, Zheng Q. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia. Sci Rep. 2019;9(1):12209.","journal-title":"Sci Rep"},{"key":"2455_CR108","doi-asserted-by":"crossref","unstructured":"Cancilla D, Rettig MP, DiPersio JF. Targeting CXCR4 in AML and ALL. Front Oncol. 2020;4;10:1672.","DOI":"10.3389\/fonc.2020.01672"},{"key":"2455_CR109","doi-asserted-by":"crossref","unstructured":"Klement L, Drube J. The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate. Front Oncol. 2023;13:1258679.","DOI":"10.3389\/fonc.2023.1258679"},{"key":"2455_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.07.017","author":"M Heiblig","year":"2018","unstructured":"Heiblig M, Elhamri M, Thomas X, Plesa A, Raffoux E, Hayette S. A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia. Leuk Res. 2018. https:\/\/doi.org\/10.1016\/j.leukres.2018.07.017.","journal-title":"Leuk Res"},{"key":"2455_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26414","author":"TM Cooper","year":"2017","unstructured":"Cooper TM, Sison EAR, Baker SD, et al. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: a pediatric oncology experimental therapeutics investigators\u2019 consortium study (POE 10\u2009\u2013\u200903). Pediatr Blood Cancer. 2017. https:\/\/doi.org\/10.1002\/pbc.26414.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2455_CR112","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.leukres.2015.09.020","volume":"39","author":"GL Uy","year":"2015","unstructured":"Uy GL, Hsu YMS, Schmidt AP, et al. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia. Leuk Res. 2015;39(12):1437\u201342.","journal-title":"Leuk Res"},{"issue":"1","key":"2455_CR113","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13402-016-0300-x","volume":"40","author":"A Caivano","year":"2017","unstructured":"Caivano A, La Rocca F, Simeon V, et al. Microrna-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. Cell Oncol. 2017;40(1):97\u2013103.","journal-title":"Cell Oncol"},{"issue":"23","key":"2455_CR114","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood-2016-09-740209","volume":"129","author":"JA Wallace","year":"2017","unstructured":"Wallace JA, Kagele DA, Eiring AM, et al. Mir-155 promotes FLT3-ITD\u2013induced myeloproliferative disease through inhibition of the interferon response. Blood. 2017;129(23):3074\u201386.","journal-title":"Blood"},{"issue":"17","key":"2455_CR115","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1182\/bloodadvances.2022007952","volume":"6","author":"DR Buelow","year":"2022","unstructured":"Buelow DR, Bhatnagar B, Orwick SJ, et al. BMX kinase mediates gilteritinib resistance in FLT3 -mutated AML through microenvironmental factors. Blood Adv. 2022;6(17):5049\u201360.","journal-title":"Blood Adv"},{"key":"2455_CR116","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018029850","author":"PJ Sung","year":"2019","unstructured":"Sung PJ, Sugita M, Koblish H, Perl AE, Carroll M. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia. Blood Adv. 2019. https:\/\/doi.org\/10.1182\/bloodadvances.2018029850.","journal-title":"Blood Adv"},{"issue":"March","key":"2455_CR117","first-page":"1","volume":"15","author":"PA Flynn","year":"2024","unstructured":"Flynn PA, Long MD, Kosaka Y, et al. Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency. Front Immunol. 2024;15(March):1\u201315.","journal-title":"Front Immunol"},{"issue":"11","key":"2455_CR118","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","volume":"24","author":"DC de Leeuw","year":"2022","unstructured":"de Leeuw DC, Ossenkoppele GJ, Janssen JJWM. Older patients with acute myeloid leukemia deserve individualized treatment. Curr Oncol Rep. 2022;24(11):1387\u2013400.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2455_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):1\u201320.","journal-title":"Mol Cancer"},{"issue":"20","key":"2455_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm12206429","volume":"12","author":"C Negotei","year":"2023","unstructured":"Negotei C, Colita A, Mitu I, et al. A review of FLT3 kinase inhibitors in AML. J Clin Med. 2023;12(20):1\u201313.","journal-title":"J Clin Med"},{"issue":"18","key":"2455_CR121","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3 -Mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"2455_CR122","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1182\/blood-2021-154247","volume":"138","author":"D Kipp","year":"2021","unstructured":"Kipp D, Loo S, Perkins AC, et al. A phase-Ib\/II clinical evaluation of Ponatinib in combination with Azacitidine in FLT3 -ITD and CBL -mutant acute myeloid leukemia (PON-AZA study). Blood. 2021;138(Supplement 1):2350\u20132350.","journal-title":"Blood"},{"issue":"3","key":"2455_CR123","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3324\/haematol.2022.281216","volume":"108","author":"KW Pratz","year":"2023","unstructured":"Pratz KW, Kaplan J, Levy M, et al. A phase Ib trial of Mivavotinib (TAK-659), a dual SYK\/FLT3 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia. Haematologica. 2023;108(3):705\u201316.","journal-title":"Haematologica"},{"issue":"December 2014","key":"2455_CR124","first-page":"1","volume":"5","author":"YY Ke","year":"2015","unstructured":"Ke YY, Singh VK, Coumar MS, et al. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci Rep. 2015;5(December 2014):1\u201312.","journal-title":"Sci Rep"},{"issue":"8","key":"2455_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines8080245","volume":"8","author":"M Eguchi","year":"2020","unstructured":"Eguchi M, Minami Y, Kuzume A, Chi SG. Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines. 2020;8(8):1\u201321.","journal-title":"Biomedicines"},{"issue":"14","key":"2455_CR126","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-20-3458","volume":"27","author":"CC Smith","year":"2021","unstructured":"Smith CC, Viny AD, Massi E, et al. Recurrent mutations in cyclin D3 confer clinical resistance to FLT3 inhibitors in acute myeloid leukemia. Clin Cancer Res. 2021;27(14):4003\u201311.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2455_CR127","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1177\/1947601910396505","volume":"1","author":"E Weisberg","year":"2010","unstructured":"Weisberg E, Roesel J, Furet P, et al. Antileukemic effects of novel first- and second-generation FLT3 inhibitors: structure-affinity comparison. Genes Cancer. 2010;1(10):1021\u201332.","journal-title":"Genes Cancer"},{"issue":"5","key":"2455_CR128","first-page":"1","volume":"14","author":"J Nitika, Wei","year":"2022","unstructured":"Nitika, Wei J, Hui AM. Role of biomarkers in FLT3 AML. Cancers (Basel). 2022;14(5):1\u201316.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2455_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109576","volume":"27","author":"DJL Coleman","year":"2024","unstructured":"Coleman DJL, Keane P, Chin PS, et al. Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD\u2009+\u2009AML through AP-1 and RUNX1. iScience. 2024;27(4):109576.","journal-title":"iScience"},{"key":"2455_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117076","author":"C Hieber","year":"2024","unstructured":"Hieber C, Mustafa AHM, Neuroth S, et al. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells. Biomed Pharmacother. 2024. https:\/\/doi.org\/10.1016\/j.biopha.2024.117076.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2455_CR131","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","volume":"2","author":"RM Stone","year":"2018","unstructured":"Stone RM, Manley PW, Larson RA, Capdeville R, Midostaurin. Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018;2(4):444\u201353.","journal-title":"Blood Adv"},{"issue":"3","key":"2455_CR132","first-page":"1","volume":"28","author":"A di Ghelli Luserna","year":"2023","unstructured":"di Ghelli Luserna A, Jandoubi M, Martinelli G, Simonetti G. Targeting proliferation signals and the cell cycle machinery in acute leukemias: novel molecules on the horizon. Molecules. 2023;28(3):1\u201323.","journal-title":"Molecules"},{"issue":"8","key":"2455_CR133","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3324\/haematol.2016.160101","volume":"102","author":"I Peschel","year":"2017","unstructured":"Peschel I, Podmirseg SR, Taschler M, et al. FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia. Haematologica. 2017;102(8):1378\u201389.","journal-title":"Haematologica"},{"issue":"9","key":"2455_CR134","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2217\/fon.14.105","volume":"10","author":"M Levis","year":"2014","unstructured":"Levis M. Quizartinib for the treatment of FLT3\/ITD acute myeloid leukemia. Futur Oncol. 2014;10(9):1571\u20139.","journal-title":"Futur Oncol"},{"issue":"10","key":"2455_CR135","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","volume":"3","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019;3(10):1581\u20135.","journal-title":"Blood Adv"},{"issue":"23","key":"2455_CR136","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","volume":"121","author":"F Ravandi","year":"2013","unstructured":"Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655\u201362.","journal-title":"Blood"},{"issue":"7","key":"2455_CR137","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2004-09-3667","volume":"106","author":"RW Stam","year":"2005","unstructured":"Stam RW, Den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005;106(7):2484\u201390.","journal-title":"Blood"},{"issue":"19","key":"2455_CR138","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1182\/bloodadvances.2018020693","volume":"2","author":"IK Siekmann","year":"2018","unstructured":"Siekmann IK, Dierck K, Prall S, et al. Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL. Blood Adv. 2018;2(19):2554\u201367.","journal-title":"Blood Adv"},{"issue":"5","key":"2455_CR139","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.2021012976","volume":"139","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Yamauchi T, Semba Y, et al. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. Blood. 2022;139(5):748\u201360.","journal-title":"Blood"},{"issue":"23","key":"2455_CR140","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2018-04-845628","volume":"132","author":"J Zhang","year":"2018","unstructured":"Zhang J, Zhang Y, Zhang M, et al. FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia. Blood. 2018;132(23):2520\u20134.","journal-title":"Blood"},{"issue":"December 2021","key":"2455_CR141","doi-asserted-by":"publisher","first-page":"110301","DOI":"10.1016\/j.cellsig.2022.110301","volume":"93","author":"P Ehm","year":"2022","unstructured":"Ehm P, Grottke A, Bettin B, J\u00fccker M. Investigation of the function of the PI3-Kinase \/ AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL). Cell Signal. 2022;93(December 2021):110301.","journal-title":"Cell Signal"},{"key":"2455_CR142","doi-asserted-by":"crossref","unstructured":"Perell\u00f3-reus P CM, Catal\u00e0 A, Caviedes-c\u00e1rdenas L. FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia. Pharmacol Res. 2020;151:104556.","DOI":"10.1016\/j.phrs.2019.104556"},{"issue":"1","key":"2455_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41525-019-0082-y","volume":"4","author":"RA Chougule","year":"2019","unstructured":"Chougule RA, Shah K, Moharram SA, Vallon-Christersson J, Kazi JU. Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation. Npj Genom Med. 2019;4(1):1\u20137.","journal-title":"Npj Genom Med"},{"issue":"1","key":"2455_CR144","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-560","volume":"10","author":"C Schult","year":"2010","unstructured":"Schult C, Dahlhaus M, Ruck S, et al. The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells. BMC Cancer. 2010;10(1):560.","journal-title":"BMC Cancer"},{"key":"2455_CR145","doi-asserted-by":"crossref","unstructured":"Manzano-Mu\u00f1oz A, Alcon C, Men\u00e9ndez P et al. MCL-1 Inhibition overcomes Anti-apoptotic adaptation to targeted therapies in B-Cell precursor acute lymphoblastic leukemia. Front Cell Dev Biol. 2021;9:695225.","DOI":"10.3389\/fcell.2021.695225"},{"issue":"354","key":"2455_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaf5309","volume":"8","author":"JT Leonard","year":"2016","unstructured":"Leonard JT, Rowley JSJ, Eide CA, et al. Targeting BCL-2 and ABL \/ LYN in Philadelphia chromosome \u2013 positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8(354):1\u201311.","journal-title":"Sci Transl Med"},{"issue":"2","key":"2455_CR147","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2004-06-2498","volume":"105","author":"P Brown","year":"2005","unstructured":"Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood. 2005;105(2):812\u201320.","journal-title":"Blood"},{"issue":"9","key":"2455_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.30503","volume":"70","author":"K Hughes","year":"2023","unstructured":"Hughes K, Evans K, Earley EJ, et al. In vivo activity of the dual SYK\/FLT3 inhibitor TAK-659 against pediatric acute lymphoblastic leukemia xenografts. Pediatr Blood Cancer. 2023;70(9):1\u201310.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2455_CR149","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"2455_CR150","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","volume":"36","author":"FG R\u00fccker","year":"2022","unstructured":"R\u00fccker FG, Du L, Luck TJ, et al. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia. 2022;36(1):90\u20139.","journal-title":"Leukemia"},{"issue":"3","key":"2455_CR151","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjh.15593","volume":"185","author":"CM Zwaan","year":"2019","unstructured":"Zwaan CM, S\u00f6derh\u00e4ll S, Brethon B, et al. A phase 1\/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia. Br J Haematol. 2019;185(3):623\u20137.","journal-title":"Br J Haematol"},{"issue":"4","key":"2455_CR152","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/bjh.19250","volume":"204","author":"R Madero-Marroquin","year":"2024","unstructured":"Madero-Marroquin R, DuVall AS, Saygin C, et al. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024;204(4):1238\u201342.","journal-title":"Br J Haematol"},{"issue":"May 2021","key":"2455_CR153","first-page":"10","volume":"14","author":"NP Horvat","year":"2022","unstructured":"Horvat NP, Logothetis CN, Zhang L, Yun S, Sweet K. Gilteritinib combined with Azacitidine as salvage therapy for b\/myeloid mixed phenotype acute leukemia. Cureus. 2022;14(May 2021):10\u20134.","journal-title":"Cureus"},{"key":"2455_CR154","doi-asserted-by":"crossref","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed\/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022;40(35):4048\u201359.","DOI":"10.1200\/JCO.22.00602"},{"key":"2455_CR155","doi-asserted-by":"crossref","unstructured":"Fu Q, Wang Y, Liu H et al. Triplet therapy with gilteritinib, venetoclax, and Azacitidine for relapsed\/refractory FLT3mut acute myeloid leukemia. Leuk Res. 2024;145:107564.","DOI":"10.1016\/j.leukres.2024.107564"},{"issue":"13","key":"2455_CR156","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42(13):1499\u2013508.","journal-title":"J Clin Oncol"},{"key":"2455_CR157","doi-asserted-by":"publisher","first-page":"117190","DOI":"10.1016\/j.ejmech.2024.117190","volume":"285","author":"CC Goodis","year":"2025","unstructured":"Goodis CC, Eberly C, Chan AM, et al. The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2\/FLT3 VEN\u2013GIL hybrid single-molecule inhibitors. Eur J Med Chem. 2025;285:117190. (December 2024).","journal-title":"Eur J Med Chem"},{"key":"2455_CR158","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1016\/S2152-2650(22)01182-X","volume":"22","author":"L Montefiori","year":"2022","unstructured":"Montefiori L, lacobucci I, Budhraja A, et al. ALL-090 highly effective combination of FLT3 and BCL2 inhibitors in a preclinical model of lineage ambiguous leukemia. Clin Lymphoma Myeloma Leuk. 2022;22:S193\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"2455_CR159","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch PM, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140(24):2594\u2013610.","journal-title":"Blood"},{"issue":"2","key":"2455_CR160","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5(2):380\u2013400.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"2455_CR161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00451-w","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6(1):1\u201311.","journal-title":"Signal Transduct Target Ther"},{"key":"2455_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM. A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev. 2022;52:1\u201333.","journal-title":"Blood Rev"},{"issue":"7","key":"2455_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30240-7","volume":"19","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perl AE, D\u00f6hner H, et al. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2018;903. https:\/\/doi.org\/10.1016\/S1470-2045(18)30240-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2455_CR164","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01617-7","volume":"17","author":"J Cortes","year":"2024","unstructured":"Cortes J. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD\u2013positive AML. J Hematol Oncol. 2024;17(1):111.","journal-title":"J Hematol Oncol"},{"key":"2455_CR165","unstructured":"FDA. FDA approves quizartinib for newly diagnosed acute myeloid leukemia. 2023:2023\u20135. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia"},{"issue":"10388","key":"2455_CR166","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet"},{"issue":"Supplement 1","key":"2455_CR167","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2024-204779","volume":"144","author":"P Montesinos","year":"2024","unstructured":"Montesinos P, Rodriguez-Veiga R, Bergua Burgues JM, et al. Final results of quiwi: a double blinded, randomized Pethema trial comparing standard chemotherapy plus Quizartinib versus placebo in adult patients with newly diagnosed FLT3 -ITD negative AML. Blood. 2024;144(Supplement 1):1512\u20131512.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2455_CR168","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2023-180482","volume":"142","author":"A Mosquera Orgueira","year":"2023","unstructured":"Mosquera Orgueira A, Perez Encinas M, Diaz Arias JA, et al. The FLT3-like gene expression signature predicts response to Quizartinib in Wild-Type FLT3 acute myeloid leukemia: an analysis of the Pethema Quiwi trial. Blood. 2023;142(Supplement 1):974\u2013974.","journal-title":"Blood"},{"issue":"2 February","key":"2455_CR169","first-page":"1","volume":"16","author":"AM Orgueira","year":"2021","unstructured":"Orgueira AM, Ra\u00edndo AP, L\u00f3pez MC, et al. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia. PLoS ONE. 2021;16(2 February):1\u20139.","journal-title":"PLoS ONE"},{"issue":"November","key":"2455_CR170","first-page":"6135","volume":"144","author":"AM Orgueira","year":"2024","unstructured":"Orgueira AM, Encinas MP, M\u00edguez CP, et al. Molecular mechanisms of Quizartinib response in FLT3-ITD negative AML: an updated analysis from the Pethema. Quiwi Trial. 2024;144(November):6135.","journal-title":"Quiwi Trial"},{"issue":"Supplement 1","key":"2455_CR171","doi-asserted-by":"publisher","first-page":"15043","DOI":"10.1182\/blood-2024-205101","volume":"144","author":"P Montesinos","year":"2024","unstructured":"Montesinos P, Cheong JW, Daver N, et al. Trial in progress: the phase 3, randomized, double-blind, placebo-controlled QuANTUM-Wild study of Quizartinib in combination with chemotherapy and as single-agent maintenance in newly diagnosed, FLT3-ITD-Negative acute myeloid leukemia. Blood. 2024;144(Supplement 1):15043.","journal-title":"Blood"},{"issue":"16","key":"2455_CR172","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","volume":"22","author":"TM Cooper","year":"2016","unstructured":"Cooper TM, Cassar J, Eckroth E, et al. A phase I study of Quizartinib combined with chemotherapy in relapsed childhood leukemia: a therapeutic advances in childhood leukemia & lymphoma (TACL) study. Clin Cancer Res. 2016;22(16):4014\u201322.","journal-title":"Clin Cancer Res"},{"issue":"15suppl","key":"2455_CR173","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2016.34.15_suppl.7008","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib besylate, a type i pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. J Clin Oncol. 2016;34(15suppl):7008\u20137008.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2455_CR174","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/JCO.23.01061","volume":"42","author":"ES Wang","year":"2024","unstructured":"Wang ES, Goldberg AD, Tallman M, et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J Clin Oncol. 2024;42(15):1776\u201387.","journal-title":"J Clin Oncol"},{"issue":"21","key":"2455_CR175","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood.V118.21.937.937","volume":"118","author":"CC Smith","year":"2011","unstructured":"Smith CC, Chin J, Wang Q, et al. Validation of FLT3-ITD as a therapeutic target in human acute myeloid leukemia. Blood. 2011;118(21):937\u2013937.","journal-title":"Blood"},{"issue":"14","key":"2455_CR176","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1073\/pnas.1320661111","volume":"111","author":"EA Lasater","year":"2014","unstructured":"Lasater EA, Lin KC, Wang Q. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014;111(14):5319\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2455_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08263-x","author":"H Zhang","year":"2019","unstructured":"Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019. https:\/\/doi.org\/10.1038\/s41467-018-08263-x.","journal-title":"Nat Commun"},{"issue":"9","key":"2455_CR178","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41375-021-01148-x","volume":"35","author":"C R\u00f6llig","year":"2021","unstructured":"R\u00f6llig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021;35(9):2517\u201325.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"2455_CR179","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1182\/blood-2020-137334","volume":"136","author":"AH Wei","year":"2020","unstructured":"Wei AH, Kennedy GA, Morris KL, et al. Results of a phase 2, randomized, Double-Blind study of Sorafenib versus placebo in combination with intensive chemotherapy in previously untreated patients with FLT3-ITD acute myeloid leukemia (ALLG AMLM16). Blood. 2020;136(Supplement 1):36\u20138.","journal-title":"Blood"},{"issue":"April","key":"2455_CR180","first-page":"1","volume":"14","author":"M Hu","year":"2024","unstructured":"Hu M, Li W, Li P, Tan J, Wang Y. A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine. Front Oncol. 2024;14(April):1\u20135.","journal-title":"Front Oncol"},{"issue":"11","key":"2455_CR181","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1002\/cncr.34182","volume":"128","author":"X Chen","year":"2022","unstructured":"Chen X, Huang J, Xu N, et al. A phase 2 study of Sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 2022;128(11):2138\u201347.","journal-title":"Cancer"},{"issue":"November","key":"2455_CR182","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1182\/blood-2024-203334","volume":"144","author":"T Zhang","year":"2024","unstructured":"Zhang T, Chi P, Fan Z, et al. Sorafenib combined with chemotherapy and donor lymphocyte infusion for patients with FLT3 Wild-Type acute leukemia relapsing after Allo-HSCT. Blood. 2024;144(November):7385.","journal-title":"Blood"},{"issue":"5","key":"2455_CR183","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bjh.13353","volume":"169","author":"W Fiedler","year":"2015","unstructured":"Fiedler W, Kayser S, Kebenko M, et al. A phase I\/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol. 2015;169(5):694\u2013700.","journal-title":"Br J Haematol"},{"issue":"5","key":"2455_CR184","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes Mutation-Based resistance. Cancer Cell. 2009;16(5):401\u201312.","journal-title":"Cancer Cell"},{"issue":"21","key":"2455_CR185","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood.2021011722","volume":"139","author":"E Berman","year":"2022","unstructured":"Berman E. How i treat chronic-phase chronic myelogenous leukemia. Blood. 2022;139(21):3138\u201347.","journal-title":"Blood"},{"issue":"1","key":"2455_CR186","first-page":"1028","volume":"10","author":"M Joseph","year":"2011","unstructured":"Joseph M, Gozgit, et al. Potent activity of Ponatinib (AP24534) in models of FLT3-Driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011;10(1):1028\u201335.","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"2455_CR187","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood-2012-07-442871","volume":"121","author":"CC Smith","year":"2013","unstructured":"Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. 2013;121(16):3165\u201371.","journal-title":"Blood"},{"key":"2455_CR188","doi-asserted-by":"crossref","unstructured":"Chevallier P, Thiebaut A, Fran\u00e7ois S et al. A phase II study of Ponatinib for prevention of relapse after allotransplantation in FLT3 internal tandem duplication mutation positive (FLT3-ITD+) acute myeloid leukemia: the PONALLO trial. Haematologica April 17, 2025.","DOI":"10.3324\/haematol.2025.287681"},{"issue":"Supplement 1","key":"2455_CR189","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2023-182091","volume":"142","author":"M Lunghi","year":"2023","unstructured":"Lunghi M, Kaiser F, Cardinali D, et al. Use of ponatinib alone or combined with other therapies in relapsed\/refractory Ph-like acute lymphoblastic leukemia. A campus ALL real-life study. Blood. 2023;142(Supplement 1):1507\u20131507.","journal-title":"Blood"},{"key":"2455_CR190","doi-asserted-by":"publisher","unstructured":"Brown PA, Kairalla JA, Hilden JM et al. Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children\u2019s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279\u20131290). https:\/\/doi.org\/10.1038\/s41375-021-01177-6). Leukemia. 2021;35(5):1527.","DOI":"10.1038\/s41375-021-01177-6"},{"issue":"16","key":"2455_CR191","first-page":"1805","volume":"79","author":"YN Lamb","year":"2019","unstructured":"Lamb YN. Pexidartinib. First Approval Drugs. 2019;79(16):1805\u201312.","journal-title":"First Approval Drugs"},{"issue":"8","key":"2455_CR192","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1182\/bloodadvances.2020001449","volume":"4","author":"CC Smith","year":"2020","unstructured":"Smith CC, Levis MJ, Frankfurt O, et al. A phase 1\/2 study of the oral FLT3 inhibitor pexidartinib in relapsed\/ refractory FLT3-ITD\u2013mutant acute myeloid leukemia. Blood Adv. 2020;4(8):1711\u201321.","journal-title":"Blood Adv"},{"key":"2455_CR193","unstructured":"Thomas EW. Phase I trial of TURALIO (Pexidartinib, PLX3397) in children and young adults with refractory leukemias and refractory solid tumors including neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) and tenosynovial giant cell tumor (TGCT). 2025. https:\/\/clinicaltrials.gov\/study\/NCT02390752"},{"issue":"Supplement 1","key":"2455_CR194","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood-2023-182361","volume":"142","author":"M Rotta","year":"2023","unstructured":"Rotta M, Ravandi F, Gandhi M, et al. Covalent-103: a phase 1, open-label, dose-escalation, and dose-expansion study of Bmf-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia (AL). Blood. 2023;142(Supplement 1):1546\u20131546.","journal-title":"Blood"},{"issue":"1","key":"2455_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-29224-5","volume":"13","author":"IR Leo","year":"2022","unstructured":"Leo IR, Aswad L, Stahl M, et al. Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. Nat Commun. 2022;13(1):1\u201319.","journal-title":"Nat Commun"},{"key":"2455_CR196","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbad143","author":"L Aswad","year":"2023","unstructured":"Aswad L, Jafari R. FORALL: an interactive shiny\/r web portal to navigate multi-omics high-throughput data of pediatric acute lymphoblastic leukemia. Bioinformatics Adv. 2023. https:\/\/doi.org\/10.1093\/bioadv\/vbad143.","journal-title":"Bioinformatics Adv"},{"issue":"12","key":"2455_CR197","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"IK Park","year":"2015","unstructured":"Park IK, Mundy-Bosse B, Whitman SP, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382\u20139.","journal-title":"Leukemia"},{"issue":"10","key":"2455_CR198","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19103198","volume":"19","author":"D Staudt","year":"2018","unstructured":"Staudt D, Murray HC, McLachlan T, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci. 2018;19(10):3198.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2455_CR199","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjh.14075","volume":"174","author":"S Randhawa","year":"2016","unstructured":"Randhawa S, Cho BS, Ghosh D, et al. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol. 2016;174(3):425\u201336.","journal-title":"Br J Haematol"},{"issue":"6","key":"2455_CR200","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41375-023-01897-x","volume":"37","author":"Y Jia","year":"2023","unstructured":"Jia Y, Zhang W, Basyal M, et al. FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4\/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia. 2023;37(6):1379\u201383.","journal-title":"Leukemia"},{"key":"2455_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni M, Crucitta S, Luculli GI, et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol Hematol. 2024;201:104424.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2455_CR202","doi-asserted-by":"publisher","first-page":"7955","DOI":"10.1021\/acs.jmedchem.4c03023","volume":"68","author":"B Liu","year":"2025","unstructured":"Liu B, Kang N, Yang F, et al. Discovery of FLT3-ITD inhibitor clifutinib: a novel biphenylacetylene urea derivative in clinical trials for the treatment of relapsed\/refractory FLT3-ITD\u2009+\u2009acute myeloid leukemia. J Med Chem. 2025;68(8):7955\u201372.","journal-title":"J Med Chem"},{"issue":"1","key":"2455_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01029-3","volume":"14","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Pardanani A. Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval. Blood Cancer J. 2024;14(1):47.","journal-title":"Blood Cancer J"},{"issue":"4","key":"2455_CR204","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1182\/bloodadvances.2021004611","volume":"6","author":"M Azhar","year":"2022","unstructured":"Azhar M, Kincaid Z, Kesarwani M, et al. Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Adv. 2022;6(4):1186\u201392.","journal-title":"Blood Adv"},{"issue":"3","key":"2455_CR205","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.beha.2017.06.001","volume":"30","author":"L Maese","year":"2017","unstructured":"Maese L, Tasian SK, Raetz EA. How is the Ph-like signature being incorporated into ALL therapy? Best Pract Res Clin Haematol. 2017;30(3):222\u20138.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"12","key":"2455_CR206","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11121966","volume":"11","author":"BJ Schmied","year":"2019","unstructured":"Schmied BJ, Lutz MS, Riegg F, et al. Induction of NK cell reactivity against B-Cell acute lymphoblastic leukemia by an fc-optimized FLT3 antibody. Cancers (Basel). 2019;11(12):1\u201315.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2455_CR207","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3324\/haematol.2022.281456","volume":"108","author":"LM Niswander","year":"2023","unstructured":"Niswander LM, Graff ZT, Chien CD, et al. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023;108(2):457\u201371.","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"2455_CR208","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood-2024-206467","volume":"144","author":"LM Niswander","year":"2024","unstructured":"Niswander LM, McClellan S, Barcenas-Lopez DA, et al. Gilteritinib augments preclinical FLT3 and CD19 CAR T cell immunotherapy in high-risk pediatric leukemias. Blood. 2024;144(Supplement 1):370\u2013370.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2455_CR209","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2024-201264","volume":"144","author":"A Mosquera Orgueira","year":"2024","unstructured":"Mosquera Orgueira A, Perez Encinas M, P\u00e9rez M\u00edguez C, et al. Enhanced validation of the FLT3 -like gene expression signature as a predictive biomarker for Quizartinib response in FLT3-ITD negative acute myeloid leukemia: expanded cohort and extended follow-up from the Pethema Quiwi trial. Blood. 2024;144(Supplement 1):1552\u20131552.","journal-title":"Blood"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02455-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:05:55Z","timestamp":1761123955000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02455-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":209,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2455"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02455-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}